CN104812747B - 用于治疗病毒感染的1,2,4‑三嗪衍生物 - Google Patents

用于治疗病毒感染的1,2,4‑三嗪衍生物 Download PDF

Info

Publication number
CN104812747B
CN104812747B CN201380050972.5A CN201380050972A CN104812747B CN 104812747 B CN104812747 B CN 104812747B CN 201380050972 A CN201380050972 A CN 201380050972A CN 104812747 B CN104812747 B CN 104812747B
Authority
CN
China
Prior art keywords
alkylamino
compound
alkyl
alkoxy
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380050972.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104812747A (zh
Inventor
V·跟巴斯
P·朱博
C·瓦罗
V·勒瓦谢
J-F·邦凡蒂
D·G·麦克格文
J·E·G·吉耶蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTITUT NATIONAL DES SCIENCES APPLIQUEES
Centre National de la Recherche Scientifique CNRS
Universite de Rouen
Original Assignee
INSTITUT NATIONAL DES SCIENCES APPLIQUEES
Centre National de la Recherche Scientifique CNRS
Universite de Rouen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSTITUT NATIONAL DES SCIENCES APPLIQUEES, Centre National de la Recherche Scientifique CNRS, Universite de Rouen filed Critical INSTITUT NATIONAL DES SCIENCES APPLIQUEES
Publication of CN104812747A publication Critical patent/CN104812747A/zh
Application granted granted Critical
Publication of CN104812747B publication Critical patent/CN104812747B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380050972.5A 2012-10-01 2013-10-01 用于治疗病毒感染的1,2,4‑三嗪衍生物 Expired - Fee Related CN104812747B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306196.2 2012-10-01
EP12306196.2A EP2712866A1 (en) 2012-10-01 2012-10-01 1,2,4-triazine derivatives for the treatment of viral infections
PCT/EP2013/070488 WO2014053516A1 (en) 2012-10-01 2013-10-01 1,2,4-triazine derivatives for the treatment of viral infections.

Publications (2)

Publication Number Publication Date
CN104812747A CN104812747A (zh) 2015-07-29
CN104812747B true CN104812747B (zh) 2017-03-08

Family

ID=46982496

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380050972.5A Expired - Fee Related CN104812747B (zh) 2012-10-01 2013-10-01 用于治疗病毒感染的1,2,4‑三嗪衍生物

Country Status (21)

Country Link
US (1) US9416114B2 (enExample)
EP (2) EP2712866A1 (enExample)
JP (1) JP6298998B2 (enExample)
KR (1) KR102138393B1 (enExample)
CN (1) CN104812747B (enExample)
AU (1) AU2013326579B2 (enExample)
BR (1) BR112015007310B1 (enExample)
CA (1) CA2886630C (enExample)
CL (1) CL2015000787A1 (enExample)
EA (1) EA026236B1 (enExample)
ES (1) ES2616496T3 (enExample)
IL (1) IL237871A (enExample)
IN (1) IN2015DN03327A (enExample)
MX (1) MX348229B (enExample)
MY (1) MY182558A (enExample)
NZ (1) NZ706354A (enExample)
PH (1) PH12015500724A1 (enExample)
SG (1) SG11201502522WA (enExample)
UA (1) UA114644C2 (enExample)
WO (1) WO2014053516A1 (enExample)
ZA (1) ZA201502240B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101946499B1 (ko) 2011-04-08 2019-02-11 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 피리미딘 유도체
EP2776439B1 (en) 2011-11-09 2018-07-04 Janssen Sciences Ireland UC Purine derivatives for the treatment of viral infections
CA2874800C (en) 2012-07-13 2021-04-06 Janssen R&D Ireland Macrocyclic purines for the treatment of viral infections
NZ705589A (en) 2012-10-10 2019-05-31 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
AU2013346793B2 (en) 2012-11-16 2018-03-08 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
KR102225233B1 (ko) 2013-02-21 2021-03-09 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
MX366481B (es) 2013-03-29 2019-07-09 Janssen Sciences Ireland Uc Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
MY188071A (en) 2013-05-24 2021-11-16 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
CN109369643B (zh) 2013-06-27 2021-05-18 爱尔兰詹森科学公司 用于治疗病毒感染和其他疾病的吡咯并[3,2-d]嘧啶衍生物
EP3027624B1 (en) 2013-07-30 2018-09-12 Janssen Sciences Ireland UC Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
WO2018002319A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Uc Dihydropyranopyrimidines for the treatment of viral infections
WO2018060317A1 (en) * 2016-09-29 2018-04-05 Janssen Sciences Ireland Uc Pyrimidine prodrugs for the treatment of viral infections and further diseases
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 2,4-二胺基喹唑啉衍生物及其醫學用途
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
CA3170551A1 (en) 2020-03-02 2021-09-10 Yong Taik Lim Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途
US20230346924A1 (en) 2020-08-04 2023-11-02 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
WO2024151953A1 (en) * 2023-01-15 2024-07-18 Viradem Inc. Compounds and methods for treating diseases caused by sars-cov-2 and other coronaviruses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485531A1 (fr) * 1980-06-25 1981-12-31 Fabre Sa Pierre Nouveaux n-oxydes de diaryl-5,6 as triazines 1-2-4, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
CN101035773A (zh) * 2004-08-10 2007-09-12 詹森药业有限公司 抑制hiv的1,2,4-三嗪-6-酮衍生物
RU2352565C1 (ru) * 2007-10-08 2009-04-20 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" 3-амино-6-ароилметил-5-гидрокси-1,2,4-триазины и способ их получения
CN101925584A (zh) * 2007-11-22 2010-12-22 阿斯利康(瑞典)有限公司 用于治疗哮喘、copd、过敏性鼻炎、过敏性结膜炎、特应性皮炎、癌症、乙型肝炎、丙型肝炎、hiv、hpv、细菌感染和皮肤病的嘧啶衍生物
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990044383A (ko) 1996-07-03 1999-06-25 나가시마 카쭈시게, 노미야마 아키히코 신규 퓨린 유도체
US6329381B1 (en) 1997-11-28 2001-12-11 Sumitomo Pharmaceuticals Company, Limited Heterocyclic compounds
EP1888587A1 (en) 2005-05-04 2008-02-20 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
CN101296907B (zh) * 2005-09-01 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485531A1 (fr) * 1980-06-25 1981-12-31 Fabre Sa Pierre Nouveaux n-oxydes de diaryl-5,6 as triazines 1-2-4, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
CN101035773A (zh) * 2004-08-10 2007-09-12 詹森药业有限公司 抑制hiv的1,2,4-三嗪-6-酮衍生物
RU2352565C1 (ru) * 2007-10-08 2009-04-20 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" 3-амино-6-ароилметил-5-гидрокси-1,2,4-триазины и способ их получения
CN101925584A (zh) * 2007-11-22 2010-12-22 阿斯利康(瑞典)有限公司 用于治疗哮喘、copd、过敏性鼻炎、过敏性结膜炎、特应性皮炎、癌症、乙型肝炎、丙型肝炎、hiv、hpv、细菌感染和皮肤病的嘧啶衍生物
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease

Also Published As

Publication number Publication date
ZA201502240B (en) 2016-05-25
EP2903976B1 (en) 2016-12-07
HK1208223A1 (en) 2016-02-26
ES2616496T3 (es) 2017-06-13
EA201500383A1 (ru) 2015-07-30
SG11201502522WA (en) 2015-05-28
US20150336907A1 (en) 2015-11-26
IN2015DN03327A (enExample) 2015-10-09
BR112015007310A2 (pt) 2017-08-08
JP2015535839A (ja) 2015-12-17
NZ706354A (en) 2018-08-31
WO2014053516A1 (en) 2014-04-10
AU2013326579A1 (en) 2015-04-09
CN104812747A (zh) 2015-07-29
BR112015007310B1 (pt) 2022-07-19
EA026236B1 (ru) 2017-03-31
CA2886630C (en) 2021-01-26
EP2712866A1 (en) 2014-04-02
PH12015500724B1 (en) 2015-06-01
US9416114B2 (en) 2016-08-16
PH12015500724A1 (en) 2015-06-01
UA114644C2 (uk) 2017-07-10
KR20150084791A (ko) 2015-07-22
IL237871A (en) 2017-04-30
MX2015004160A (es) 2016-02-05
CL2015000787A1 (es) 2015-10-02
MY182558A (en) 2021-01-25
KR102138393B1 (ko) 2020-08-14
JP6298998B2 (ja) 2018-03-28
EP2903976A1 (en) 2015-08-12
MX348229B (es) 2017-05-31
CA2886630A1 (en) 2014-04-10
AU2013326579B2 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
CN104812747B (zh) 用于治疗病毒感染的1,2,4‑三嗪衍生物
JP6501948B2 (ja) ウイルス感染治療のための大環状デアザプリノン
DK2812331T3 (en) PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
KR102217111B1 (ko) 바이러스 감염 및 다른 질환 치료를 위한 피롤로[3,2-d]피리미딘 유도체
CN105473592B (zh) 用于治疗病毒感染和其他疾病的吡咯并[3,2-d]嘧啶衍生物
DK2882721T3 (en) ALKYLPYRIMIDINE DERIVATIVES FOR TREATING VIRAL INFECTIONS AND ADDITIONAL DISEASES
JP2014512360A (ja) ウイルス感染治療用のピリミジン誘導体
KR20210028285A (ko) 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
HK1208223B (en) 1,2,4-triazine derivatives for the treatment of viral infections
HK1242310A1 (en) Purine derivatives for the treatment of viral infections
HK1192547A (en) Pyrimidine derivatives for the treatment of viral infections
HK1192547B (en) Pyrimidine derivatives for the treatment of viral infections
HK1201254B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
HK1197678A (en) Purine derivatives for the treatment of viral infections
HK1209412B (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
HK1207636B (zh) 用於治疗病毒感染和另外的疾病的烷基嘧啶衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1208223

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1208223

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170308

CF01 Termination of patent right due to non-payment of annual fee